Healthcare -
Medical - Devices - NASDAQ - US
$ 8.0
-4.19 %
$ 209 M
Market Cap
-3.74
P/E
1. INTRINSIC VALUE
Balance Sheet
CVRx, Inc.
| Current Assets | 130 M |
| Cash & Short-Term Investments | 106 M |
| Receivables | 9.27 M |
| Other Current Assets | 14.6 M |
| Non-Current Assets | 3.6 M |
| Long-Term Investments | 0 |
| PP&E | 3.57 M |
| Other Non-Current Assets | 27 K |
| Current Liabilities | 10.8 M |
| Accounts Payable | 2.58 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 8.18 M |
| Non-Current Liabilities | 51.6 M |
| Long-Term Debt | 50.2 M |
| Other Non-Current Liabilities | 1.45 M |
EFFICIENCY
Earnings Waterfall
CVRx, Inc.
| Revenue | 51.3 M |
| Cost Of Revenue | 8.33 M |
| Gross Profit | 43 M |
| Operating Expenses | 102 M |
| Operating Income | -59.5 M |
| Other Expenses | 475 K |
| Net Income | -60 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CVRx, Inc.
| Net Income | -60 M |
| Depreciation & Amortization | 619 K |
| Capital Expenditures | -1.36 M |
| Stock-Based Compensation | 19 M |
| Change in Working Capital | 949 K |
| Others | 3.3 M |
| Free Cash Flow | -40.5 M |
Wall Street Analysts Price Targets
CVRx, Inc.
Wall Street analysts predict an average 1-year price target for CVRX of $14.3 , with forecasts ranging from
a
low of
$12 to a high of $16 .
CVRX Lowest Price Target
Wall Street Target
12 USD
50.00%
CVRX Average Price Target
Wall Street Target
14.3 USD
78.57%
CVRX Highest Price Target
Wall Street Target
16 USD
100.00%
4. DIVIDEND
ANALYSIS
CVRX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CVRx, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
19.4 K USD 1
9-12 MONTHS
0 USD 0
Bought
1.07 M USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
323 K USD 2
9-12 MONTHS
7. News
CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
zacks.com
- 2 weeks ago
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026.
globenewswire.com
- 2 weeks ago
CVRx: Sell-Off Ignores Its True Potential
CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up.
seekingalpha.com
- 1 month ago
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast.
globenewswire.com
- 2 months ago
CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kevin Hykes - President & CEO Jared Oasheim - CFO Mike Vallie - IR, ICR Healthcare Conference Call Participants Macauley Kilbane - William Blair Nelson Cox - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Operator Good day, everyone, and welcome to today's CVRx Q1 2025 earnings call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 2 months ago
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $1.04 per share a year ago.
zacks.com
- 2 months ago
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 3 months ago
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
globenewswire.com
- 3 months ago
CVRx Inc: Overreaction Creates Buying Opportunity
CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness.
seekingalpha.com
- 3 months ago
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday.
benzinga.com
- 3 months ago
CVRx Reports Preliminary First Quarter 2025 Financial Results
First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024
globenewswire.com
- 3 months ago
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction
globenewswire.com
- 5 months ago
8. Profile
Summary
CVRx, Inc. CVRX
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 209 M
Dividend Yield
0.00%
Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Contact
9201 West Broadway Avenue, Minneapolis, MN, 55445
https://www.cvrx.com
IPO
Date
June 30, 2021
Employees
206
Officers
Ms. Jonelle R. Burnham
Vice President & General Counsel
Ms. Bonnie Handke M.B.A., R.N.
Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics
Mr. Kevin Hykes
President, Chief Executive Officer & Director
Ms. Tonya A. Austin SPHR
Chief Human Resources Officer
Mr. Robert Allen John
Chief Revenue Officer
Mr. Paul Pignato
Vice President of Research, Development and Operations
Mr. Paul Verrastro
Chief Marketing & Strategy Officer
Dr. Philip B. Adamson M.D., M.Sc.
Chief Medical Officer
Mr. Jared Oasheim
Chief Financial Officer